GlassScriptPhysician profile
Raju B Ray
NPI 1487652186
$3,965.38
in general payments reported to CMS, 2019-2025
28 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $63.32 · 2021: $631 · 2022: $287 · 2023: $754 · 2024: $949 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,407 · Education: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,406.80 |
| Education | $389.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $482.48 | 2020-2025 | Terlivaz, Acthar |
| Opko Pharmaceuticals, LLC | $378.86 | 2023 | Rayaldee |
| Amgen INC. | $357.57 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $335.59 | 2023-2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.31 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $232.88 | 2020-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $213.62 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $179.85 | 2022-2024 | Lupkynis |
| Calliditas Therapeutics US INC. | $151.94 | 2024-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $142.41 | 2021-2024 | Benlysta |
| Boston Scientific Corporation | $138.41 | 2021 | |
| Novartis Pharmaceuticals Corporation | $112.59 | 2023-2025 | |
| Horizon Therapeutics Plc | $106.17 | 2021 | |
| Alexion Pharmaceuticals, INC. | $103.77 | 2019 | |
| Outset Medical INC | $100.82 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $82.89 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $80.37 | 2024-2025 | Ibsrela |
| Apellis Pharmaceuticals, INC. | $59.85 | 2025 | Empaveli |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $55.02 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $52.28 | 2019-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $51.22 | 2025 | |
| Akebia Therapeutics INC | $51.01 | 2025 | Vafseo |
| Ani Pharmaceuticals, INC. | $49.97 | 2023-2024 | Purified Cortrophin Gel |
| Nxstage Medical, INC. | $46.80 | 2019 | |
| Kyowa Kirin, INC. | $29.22 | 2025 | |
| Vifor Pharma, INC. | $23.07 | 2025 | Veltassa |
| Ultragenyx Pharmaceutical INC. | $21.44 | 2024 | Crysvita |
| Janssen Pharmaceuticals, INC | $16.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raju Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.